Anti-SARS-CoV-2 Monoclonal Antibody Distribution to High-risk Medicare Beneficiaries, 2020-2021.

Behr, Caroline L; Joynt Maddox, Karen E; Meara, Ellen; Epstein, Arnold M; Orav, E John; Barnett, Michael L

Behr, Caroline L; Joynt Maddox, Karen E; Meara, Ellen; Epstein, Arnold M; Orav, E John; Barnett, Michael L.

Behr CL; Harvard Medical School, Boston, Massachusetts.
Joynt Maddox KE; Department of Internal Medicine, Washington University School of Medicine in St Louis, St Louis, Missouri.
Meara E; Associate Editor, JAMA.
Epstein AM; Geisel School of Medicine at Dartmouth College, Lebanon, New Hampshire.
Orav EJ; Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Barnett ML; Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

JAMA ; 327(10): 980-983, 2022 03 08.

Article in English | MEDLINE | ID: covidwho-1763142

Subject(s)

Antibodies, Monoclonal/therapeutic use; COVID-19 Drug Treatment; Humans; Medicare; Prescription Drugs/supply & distribution; Risk Assessment; United States

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Antibodies, Monoclonal Type of study: Prognostic study Limits: Humans Country/Region as subject: North America Language: English Journal: JAMA Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google